BBIO
BridgeBio Pharma, Inc. · Healthcare · Biotechnology
Señales de momentum (gestores comparables):
amplitud de titulares -5.3% ·
flujo de acciones -3.1% ·
nuevas posiciones netas -5.6%
· fórmula
Distribución amplia: acciones en descenso y menos titulares
Todas las cifras de propiedad: únicamente gestores 13F seguidos, posiciones en acciones ordinarias, período de referencia Q2 2025
| Trimestre | Titulares | Δ | Acciones | Valor declarado | Nuevo | Cierres |
|---|---|---|---|---|---|---|
| Q3 2026 | 2 | 0 | 26.23K | $1.72M | n/a | −1 |
| Q2 2026 | 132 | +3 | 120.71M | $8.69B | +10 | −8 |
| Q1 2026 | 133 | +3 | 129.51M | $9.40B | +8 | −6 |
| Q4 2025 | 129 | +2 | 135.35M | $9.88B | +4 | −1 |
| Q3 2025 | 19 | -1 | 71.67M | $3.72B | n/a | −2 |
| Q2 2025 | 18 | -1 | 70.97M | $3.06B | +1 | −2 |
| Q1 2025 | 16 | +3 | 40.50M | $1.40B | +3 | n/a |
| Q4 2024 | 13 | 0 | 40.68M | $1.12B | +1 | −1 |
| Q3 2024 | 12 | -1 | 35.94M | $914.95M | n/a | −1 |
| Q2 2024 | 13 | n/a | 36.42M | $922.50M | n/a | n/a |
| # | Gestor | Acciones | Δ acciones | Valor | Su ponderación | Mantenida | ||
|---|---|---|---|---|---|---|---|---|
| 1 | Viking Global Investors ✦ | 18.56M | -15.9% | $801.22M | 2.3% | ▼ Trim | 5 | SEC ↗ |
| 2 | The Vanguard Group ✦ (pasivo) | 16.48M | n/a | $711.82M | 0.0% | n/c | 1 | SEC ↗ ×5 |
| 3 | BlackRock ✦ (pasivo) | 14.26M | n/a | $615.72M | 0.0% | n/c | 1 | SEC ↗ ×20 |
| 4 | State Street Global Advisors ✦ (pasivo) | 5.90M | +2.6% | $254.62M | 0.0% | ▲ Add | 3 | SEC ↗ ×2 |
| 5 | Geode Capital Management ✦ (pasivo) | 3.68M | +5.1% | $158.99M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 6 | Two Sigma Investments ✦ | 2.34M | +177.4% | $101.00M | 0.2% | ▲ Add | 5 | SEC ↗ |
| 7 | D. E. Shaw & Co. ✦ | 2.08M | +2403.0% | $89.87M | 0.1% | ▲ Add | 2 | SEC ↗ ×2 |
| 8 | Fidelity (FMR) ✦ | 2.03M | n/a | $87.54M | 0.0% | n/c | 1 | SEC ↗ ×4 |
| 9 | Norges Bank ✦ (pasivo) | 1.96M | +57.2% | $84.49M | 0.0% | ▲ Add | 5 | SEC ↗ |
| 10 | T. Rowe Price ✦ | 961.22K | -17.5% | $41.51M | 0.0% | ▼ Trim | 5 | SEC ↗ ×2 |
| 11 | Millennium Management ✦ | 620.46K | +158.6% | $26.79M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 12 | PRIMECAP Management ✦ | 588.71K | -35.5% | $25.42M | 0.0% | ▼ Trim | 5 | SEC ↗ |
| 13 | Marshall Wace ✦ | 422.71K | +0.2% | $18.25M | 0.0% | ▲ Add | 5 | SEC ↗ ×2 |
| 14 | Citadel Advisors ✦ | 332.32K | -88.7% | $14.35M | 0.0% | ▼ Trim | 5 | SEC ↗ ×3 |
| 15 | Adage Capital Partners ✦ | 301.36K | -41.7% | $13.01M | 0.0% | ▼ Trim | 3 | SEC ↗ |
| 16 | Renaissance Technologies ✦ | 245.95K | Nuevo | $10.62M | 0.0% | New | 1 | SEC ↗ |
| 17 | AQR Capital Management ✦ | 157.81K | +17.5% | $6.81M | 0.0% | ▲ Add | 5 | SEC ↗ ×5 |
| 18 | Wellington Management ✦ | 56.67K | -5.6% | $2.45M | 0.0% | ▼ Trim | 5 | SEC ↗ ×4 |
"Their weight" = la participación de la posición en el valor de renta variable 13F reportado por ese manager: la medida de convicción. ✦ = manager curado.
Nuevos compradores
| Renaissance Technologies | $10.62M | 0.0% |
Posición cerrada
| Duquesne Family Office | $15.14M | era 0.5% |
| Point72 Asset Management | $6.87M | era 0.0% |
Contexto de mercado completo: entre TODOS los filers 13F (datos estructurados SEC, Q1 2026): 1 tenedores, 15.30K acciones, $1,136 declarado. Este es un período diferente y anterior al de las cifras del universo rastreado que figuran arriba, y ambos nunca se mezclan.
Qué más suelen tener los titulares rastreados de este valor: recuentos de titularidad compartida, no relaciones fundamentales.
Compras en mercado abierto (P)
Sin compras en mercado abierto por parte de insiders en nuestra ventana de cobertura.
Ventas en mercado abierto (S)
Officer, Director · 1.28K acc. · $88,980
Officer, Director · 8.72K acc. · $601,868
Officer, Director · 1.80K acc. · $152,436
Officer, Director · 100 acc. · $8,565
Officer, Director · 8.10K acc. · $679,256
Officer, Director · 1.90K acc. · $154,184
Officer, Director · 17.28K acc. · $1.42M
Officer, Director · 14.60K acc. · $1.21M
Officer, Director · 1.20K acc. · $100,444
Las adjudicaciones, ejercicios y retenciones fiscales nunca se contabilizan aquí como compras o ventas. Metodología
4.2% de clase · Ver presentación original ante la SEC ↗
5.0% de clase · Ver presentación original ante la SEC ↗